SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0000950142-21-001848
Filing Date
2021-06-03
Accepted
2021-06-03 17:30:14
Documents
2
Group Members
DANIEL JAVITTJONATHAN C. JAVITT

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13D eh210157301_13d-nrx.htm SC 13D 67866
2 EXHIBIT 1 eh210157301_ex01.htm EX-99.1 3616
  Complete submission text file 0000950142-21-001848.txt   72941
Mailing Address 1201 NORTH MARKET STREET SUITE 111 WILMINGTON DE 19801
Business Address
Javitt Jonathan C (Filed by) CIK: 0001303782 (see all company filings)

Type: SC 13D

Mailing Address 1201 N. MARKET STREET SUITE 111 WILMINGTON DE 19801
Business Address 1201 N. MARKET STREET SUITE 111 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Subject) CIK: 0001719406 (see all company filings)

IRS No.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-90195 | Film No.: 21993732
SIC: 2834 Pharmaceutical Preparations